Dan Vogl, MD, discusses current clinical trials in drug therapy for relapsed and refractory myeloma, including carfilzomib, pomalidomide, ibrutinib, the monoclonal antibodies, the HDAC inhibitors and the oral proteosome inhibitors, and reviews the many clinical trials ongoing at Penn Medicine in the field.
Related Links
- Clinical Briefing: Restoration of Immunity in Lymphopenic Patients with Cancer via Immunotherapy with Vaccination and Adoptive T cell Transfer
- Case Study: A 51yearold man with a lytic lesion in the 7th rib, a compression fracture at T12, monoclonal IgA antibody in his blood, and a bone marrow biopsy showing 46% plasma cells, all consistent with the diagnosis of multiple myeloma
- Dr. Vogl’s Profile
Published
June 3, 2015
Created by
BROADCASTMED